"Clinical experiences with drospirenone: from reproductive to postmenopausal years". Maturitas. 60 (2): 78–91. doi:10.1016/j.maturitas.2008.03.009. PMID 18468818. Rapkin AJ, Sorger SN, Winer SA (February 2008). "Drospirenone/ethinyl estradiol". Drugs Today. 44 (2): 133–45. doi:10.1358/dot.2008.44.2.1191057. PMID 18389090. S2CID 32413831. Rapkin AJ, Winer SA (May 2007). "Drospirenone: a novel progestin". Expert Opin Pharmacother. 8 (7): 989–99. doi:10.1517/14656566.8.7.989. PMID 17472544. S2CID 6954183. Rapkin RB, Creinin MD (October 2011). "The combined oral contraceptive pill containing drospirenone and ethinyl estradiol plus levomefolate calcium". Expert Opin Pharmacother. 12 (15): 2403–10. doi:10.1517/14656566.2011.610791. PMID 21877996. S2CID 40231903. Rübig A (October 2003). "Drospirenone: a new cardiovascular-active progestin with antialdosterone and antiandrogenic properties". Climacteric. 6 Suppl 3: 49–54. PMID 15018248. Scheinfeld NS (2007). "Yaz (3 mg drospirenone/20 microg ethinyl estradiol)". Skinmed. 6 (6): 289. doi:10.1111/j.1540-9740.2007.07338.x. PMID 17975349. Sehovic N, Smith KP (May 2010). "Risk of venous thromboembolism with drospirenone in combined oral contraceptive products". Ann Pharmacother. 44 (5): 898–903. doi:10.1345/aph.1M649. PMID 20371756. S2CID 8248469. Shulman LP (June 2006). "A review of drospirenone for safety and tolerability and effects on endometrial safety and lipid parameters contrasted with medroxyprogesterone acetate, levonorgestrel, and micronized progesterone". J Womens Health (Larchmt). 15 (5): 584–90. doi:10.1089/jwh.2006.15.584. PMID 16796485. Simoncini T, Genazzani AR (February 2010). "A review of the cardiovascular and breast actions of drospirenone in preclinical studies". Climacteric. 13 (1): 22–33. doi:10.3109/13697130903437375. PMID 19938948. S2CID 4306359. Sitruk-Ware R (October 2005). "Pharmacology of different progestogens: the special case of drospirenone". Climacteric. 8 Suppl 3: 4–12. doi:10.1080/13697130500330382. PMID 16203650. S2CID 24205704. Thorneycroft IH (November 2002). "Evolution of progestins. Focus on the novel progestin drospirenone".
Urofollitropin is a purified form of follicle-stimulating hormone (FSH) that is manufactured by extraction from human urine and then purified to remove various proteins and other substances. FSH is important in the development of follicles (eggs) produced by the ovaries. Given by subcutaneous injection, it is used in combination with human chorionic gonadotropin (hCG) to assist in ovulation and fertility. It is also used with in vitro fertilization methods. The dosage is adjusted to each individuals response.The most common side effects are abdominal or pelvic pain, bloating, as well as redness, pain or swelling at the injection site. Follitropin is possibly associated with increased risk of endometrial carcinoma. It is not for use during pregnancy, as there is evidence for birth defects under follitropin treatment.Bravelle sold in the United States from March 2014 through October 2015 is subject to a recall and refund by its maker, Ferring Pharmaceuticals, because certain batches of the medicine had a lower strength than stated. References
External links
Bravelle, by Ferring Pharmaceuticals, Switzerland
Fostimon by Institut Biochemique SA, Switzerland